No Data
No Data
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
Live webcast presentation on Wednesday, April 3rd at 1:35 PM ETOCALA, Fla., March 28, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced that Thomas K. Equels,
Earnings Scheduled For March 26, 2024
Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million. • AIM ImmunoTech (AMEX:AIM) is estimated to report
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
OCALA, Fla., March 26, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") announced today that management will host a conference call and webcast to discuss the Company's Q4/F
AIM ImmunoTech And 3 Other Stocks Under $3 Insiders Are Buying
The Dow Jones index closed lower by over 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders int
AIM ImmunoTech Announces Publication of Positive Findings From a Study Evaluating Ampligen in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through AmpligenOCALA, Fla., March 25, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM") t
AIM ImmunoTech(AIM.US) Director Buys US$15,000.18 in Common Stocks
$AIM ImmunoTech(AIM.US)$ Director BRYAN NANCY purchased 38,462 shares of Common Stocks on Mar 21, 2024 at an average price of $0.39 for a total value of $15,000.18.Source: Announcement What is stateme
No Data